Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COSYN

Financiado

Cerrado

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and ha... ver más

31/12/2020

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 14 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-12-31

PHC-03-2015: Understanding common mechanisms of...

I+D

Cerrada hace 10 años

0% 99% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

14 Participantes

675.00K€ | Lider

WECF INTERNATIONAL

50.00K€ | Participante

CARDIFF UNIVERSITY

225.00K€ | Participante

UKB

600.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CANDY Comorbid Analysis of Neurodevelopmental Disorders and Epilep... 6M€ Cerrado

PhenoConnectomics Pheno connectomics of human neurodevelopmental diseases 174K€ Cerrado

Syn2Psy Synaptic Dysfunction in Neuropsychiatric Disorders 4M€ Cerrado

GIDE Molecular diversification of inhibitory neurons during devel... 1M€ Cerrado

CELLSYNCIRCUITS CELLULAR AND SYNAPTIC DISSECTION OF THE NEURONAL CIRCUITS OF... 100K€ Cerrado

CODIP Cortical Disorganization in Psychosis. Neurophysiological... 222K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2015-12-09
Fecha Fin: 2020-12-31

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide industry-standard cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person. COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in decoding the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores